Drug intelligence / Profile preview

momordica charantia-derived extracellular vesicles

Development stage
Preclinical
Modality
Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Oral, Intravenous
01

Overview

Momordica charantia-derived extracellular vesicles (MCEVs) are nanoscale vesicles isolated from the plant Momordica charantia (bitter melon), a food and medicinal plant known for its antioxidant and anti-inflammatory properties. These plant-derived extracellular vesicles have demonstrated significant antioxidant activity in vitro and in vivo. Mechanistically, MCEVs act as free radical scavengers, reducing oxidative stress by lowering reactive oxygen species (ROS) levels and restoring mitochondrial function. They also modulate signaling pathways related to cell survival and inflammation—such as increasing p-AKT/AKT and p-ERK/ERK ratios—and promote cell proliferation while suppressing apoptosis. Preclinical studies show that MCEVs can protect against radiation-induced heart disease by mitigating myocardial injury and fibrosis, as well as restore colon health in models of ulcerative colitis through regulation of oxidative damage and inflammatory factors[1][2]. These findings suggest potential applications for MCEVs both as therapeutic agents for diseases involving oxidative stress or inflammation (e.g., cardiovascular injury, ulcerative colitis) and as drug delivery vectors.

Other names
MCEVsMCELNsMomordica charantia EVsMomordica charantia nanovesicles

Beyond the preview

Go deeper on momordica charantia-derived extracellular vesicles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on momordica charantia-derived extracellular vesicles.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call